Author:
Pauleikhoff D.,Bertram B.,Claessens D.
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. RADIANCE, Wolf S, Balciuniene VJ, Laganovska G et al (2014) RADIANCE Study Group RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia, original research article. Ophthalmology 121:682–692
2. Baba T, Kubota-Taniai M, Kitahashi M et al (2010) Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 94:864–870
3. Bandello F (2013) Twelve-month efficacy and safety of ranibizumab 0.5 mg(RBZ) versus verteporfin photodynamic therapy(vPDT) in the treatment of visual impairment(VI) due to choroidal neovascularization(CNV) secondary to pathologic myopia(PM) ARVO abstract, Program # 1247
4. Bandello F, Parodi MB, Iacono P, Papayannis A et al (2013) Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia. Retina 33:593–597
5. Bressler NM, Arnold J, Benchaboune M et al (2002) Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition’s impact on vision outcomes-TAP report No. 3. Arch Ophthalmol 120:1443–1454
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献